BioSpace News Archive

Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, today announced its launch and the closing of a $65 million series A round.

A certain biological pathway, a set of linked reactions in the body, drives the inflammation seen in the skin disease psoriasis, a new study finds.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented late-breaking data from the NOTUS Phase 3 trial evaluating the investigational use of Dupixent® (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy (nearly all on triple therapy) and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL).

GC Biopharma and Novel Pharma announced that its jointly developed MPS IIIA ‘GC1130A’ treatment has received FDA IND approval.

Spago Nanomedical AB announced that both of the clinical sites in the phase I/IIa study Tumorad-01 are actively recruiting patients.

Fractyl Health, Inc., a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes, presented new data from its preclinical Rejuva pancreatic gene therapy program as part of an oral presentation on Sunday, May 19th, at Digestive Disease Week 2024 in Washington, D.C.

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, will present new biomarker data suggesting that ALS patients may benefit from longer-term treatment with debamestrocel.

Elite Pharmaceuticals, Inc. announced that it received approval from the US Food and Drug Administration for an Abbreviated New Drug Application for generic Methotrexate Sodium 2.5 mg tablets.

Arrowhead Pharmaceuticals, Inc. announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society 2024 International Conference.

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex ® (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use.